Gyre Therapeutics (GYRE) Profit After Tax (2010 - 2026)
Gyre Therapeutics (GYRE) reported Profit After Tax of -$9.9 million for Q1 2026, down 364.01% year-over-year from $3.7 million in Q1 2025, and down 621.67% quarter-over-quarter from -$1.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Profit After Tax (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Profit After Tax data on file, last reported at -$9.9 million in Q1 2026.
- Profit After Tax for Q1 2026 came in at -$9.9 million, down 364.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.7 million (down 131.73% YoY), and the FY2025 annual result was $9.9 million, down 44.8% from the prior year.
- Profit After Tax fell to -$9.9 million in Q1 2026 per GYRE's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
- A 5-year average of -$3.7 million and a median of $2.9 million in 2024 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2026: Profit After Tax jumped 359.09% in 2022, then plunged 364.01% in 2026.
- A 5-year view of Profit After Tax shows it stood at -$27.9 million in 2022, then slumped by 261.95% to -$101.0 million in 2023, then soared by 100.56% to $569000.0 in 2024, then sank by 340.07% to -$1.4 million in 2025, then plunged by 621.67% to -$9.9 million in 2026.
- Business Quant data shows GYRE's Profit After Tax at -$9.9 million in Q1 2026, -$1.4 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | -9.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.86 Mn |
| Dec 31, 2025 | -1.37 Mn |
| Sep 30, 2025 | 5.94 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 569,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 4.54 Mn |
| Mar 31, 2024 | 9.94 Mn |
| Dec 31, 2023 | -100.98 Mn |
| Sep 30, 2023 | 7.51 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Mar 31, 2023 | 4.22 Mn |
| Dec 31, 2022 | -27.90 Mn |
| Sep 30, 2022 | -4.88 Mn |
| Jun 30, 2022 | 51.63 Mn |
| Mar 31, 2022 | -14.54 Mn |
| Dec 31, 2021 | -20.33 Mn |
| Sep 30, 2021 | -25.24 Mn |
| Jun 30, 2021 | -19.93 Mn |